Result of General Meeting
Rhea-AI Summary
Biodexa Pharmaceuticals (Nasdaq: BDRX) reported that all four resolutions at its July 29, 2026 General Meeting were passed. Resolutions 1 and 4 reduce the number of ordinary shares by a factor of 10,000 while keeping the nominal value at £0.000001 per share.
From July 30, 2026, the ordinary share per ADS ratio changes by 10,000, from 500,000:1 to 50:1, with the share reorganization effective at 08:00 BST (03:00 EDT. Biodexa said this is not a reverse split and proportional ownership is unchanged except for fractional entitlements. After the reorganization, 51,453,281 ordinary shares will be outstanding, equivalent to 1,029,063 ADSs, the same ADS total as before. Resolutions 2 and 3 authorize directors to allot shares on a non-pre-emptive basis.
Positive
- All four General Meeting resolutions approved on July 29, 2026
- Post‑reorganization ordinary share count set at 51,453,281 shares, equivalent to 1,029,063 ADSs
Negative
- Directors granted authority to allot ordinary shares on a non-pre-emptive basis, enabling issuance without pre-emption rights
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 30 | Annual meeting result | Positive | +3.1% | Ordinary resolutions passed with voting majorities between 73% and 94%. |
| Jun 30 | Equity financing | Negative | +2.1% | Biodexa priced approximately $3.5 million of equity financings and warrant transactions. |
| Jun 29 | Clinical trial expansion | Positive | -2.4% | Health Canada approved expansion of the Serenta Phase 3 trial into Canada. |
| Jun 17 | Meeting postponement | Negative | +1.7% | The Annual General Meeting was adjourned because of a lack of quorum. |
| May 14 | Share reorganization proposal | Negative | -8.5% | Biodexa proposed a 10,000:1 share consolidation and an ordinary share-to-ADS ratio change. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
BDRX showed mixed historical reactions to corporate and financing announcements, with positive reactions to two meeting-related events and a negative reaction to the prior share-capital reorganization proposal.
Key Terms
ads financial
nominal value financial
non-pre-emptive basis financial
fractional entitlements financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
July 29, 2026
Biodexa Pharmaceuticals PLC
Result of General Meeting
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces that at its General Meeting held earlier today, all four resolutions put to the Company’s shareholders were duly passed.
The full text of, inter alia, the resolutions proposed and passed at the General Meeting can be found in the Notice of the General Meeting on the Company's website at: https://biodexapharma.com/investors/corporate-governance/#agms.
The effect of resolutions 1 and 4 is solely to reduce the number of ordinary shares outstanding by a factor of 10,000 while maintaining the nominal, or par, value of
The share reorganization and change in ordinary share/ADS ratio will be effective from 08.00 BST (03.00 EDT) tomorrow July 30, 2026. Following the share capital reorganization there will be 51,453,281 ordinary shares of
The effect of resolutions 2 and 3 is to grant the Directors the authority to allot ordinary shares on a non-pre-emptive basis.
ENDS
About Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, MTX240 under development for Gastrointestinal Stromal Tumors (GIST) and tolimidone, under development for the treatment of type 1 diabetes.
eRapa is a proprietary oral capsule formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis.
MTX240 is a molecular glue, bringing two intracellular proteins, PDE3a and SLFN12, specifically co-expressed by GIST cancer cells, into close proximity to form a stable complex. This interaction stabilizes SLFN12, enabling it to drive RNase-mediated apoptosis in GIST cells through a mechanism independent of KIT or PDGFR signalling.
Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent.
Biodexa’s headquarters and R&D facility is in Cardiff, UK. For more information visit www.biodexapharma.com.
Forward-Looking Statements
Certain statements in this announcement may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management’s belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved.” Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein.
Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.
